Global Parkinson's Disease Therapeutics Market, Competitive Strategies and Forecasts, 2026 - ResearchAndMarkets.com

DUBLIN--()--The "Global Parkinson's Disease Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.

The global Parkinson's disease therapeutics market was valued at US$ 2.41 Bn in 2017, and is expected to reach US$ 3.95 Bn by 2026 expanding at a CAGR of 5.6% from 2018 to 2026.

Parkinson's disease is a type of progressive movement disorder, characterized by muscle rigidity, and tremors. The global Parkinson's disease therapeutics market will grow significantly over the forecast period, majorly due to presence of late stage pipeline drugs such as APL-130277, Accordion Pill, P2B-001, ND0612H etc. and rising incidence of the disease.

For the purpose of the study, the global Parkinson's disease therapeutics market is categorized on the basis of drug class such as dopamine agonists, levodopa/carbidopa, anticholinergic drugs, monoamine oxidase B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors and adenosine A2 receptor antagonist. Levodopa coupled with carbidopa remains the standard treatment of Parkinson's disease which shows fewer adverse effect in short-term use. Dopamine agonists are widely accepted for treatment of PD used as alone or in combination with levodopa/carbidopa.

At present, North America leads the global PD therapeutics market owning to larger patient pool, advantage of early diagnosis, developed healthcare infrastructure and increase in prevalence of PD. It is predicted that PD therapeutics market in Asia Pacific will demonstrate lucrative growth over the forecast period because of rising prevalence of PD and improving healthcare infrastructure with developing economic condition.

Key Topics Covered:

Chapter 1. Preface

Chapter 2. Executive Summary

Chapter 3. Parkinson's Disease Therapeutics: Market Dynamics and Outlook

Chapter 4. Global Parkinson's Disease Therapeutics Market, by Drug Class, 2016 - 2026 (US$ Mn)

Chapter 5. Global Parkinson's Disease Therapeutics Market, by Geography, 2016 - 2026 (US$ Mn)

Chapter 6. Company Profiles

  • Abbvie, Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim GmbH
  • F. Hoffman-La Roche
  • GlaxoSmithKline Plc.
  • H. Lundbeck A/S
  • Impax Labs, Inc.
  • Newron Pharmaceuticals SpA
  • Novartis AG
  • Orion Corporation
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

For more information about this report visit https://www.researchandmarkets.com/research/323fkl/global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Central Nervous System Drugs